Compounds · subcategory
Other compounds
Anything not covered by a dedicated subcategory, including research-use-only material with no human data.
22 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Other compounds category
Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+8 | 12 | 51k | 7mo |
|
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Asking about Research-use-only status directly, because I…
|
2 | 309 | 9mo | |
|
Compounds this community declines to help with, and why — does this still hold?
Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post,…
|
+3 | 7 | 26k | 7h |
|
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. What changes if the standard account of…
|
+7 | 11 | 31k | 19h |
|
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. Asking about research-use-only status directly, because I…
|
+72 | 81 | 44k | 1d |
|
Why catalogue breadth is not evidence of anything
Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. What changes if the standard account of catalogue breadth is wrong?…
|
2 | 38k | 2d | |
|
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. I was wrong about naming conventions for research…
|
+21 | 25 | 4.9k | 22d |
|
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…
|
+35 | 39 | 688 | 5mo |
|
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Reading back through what has been written here about AOD-9604, three…
|
+40 | 44 | 2.8k | 6mo |
|
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…
|
+100 | 108 | 1.3k | 8mo |
|
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
|
+86 | 97 | 62k | 8mo |
|
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…
|
+81 | 87 | 35k | 10mo |
|
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since What changes if the standard account of catalogue breadth is wrong? I ask…
|
+62 | 66 | 26k | 10mo |
|
Coming back to: When "no data" is the complete and final answer
When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about the compound itself rather than about a trial of it. I…
|
+77 | 82 | 12k | 11mo |
|
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…
|
+107 | 119 | 11k | 12mo |
|
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Asking about sequence verification directly, because I have…
|
+104 | 114 | 10k | 12mo |
|
Second pass at: How to research a compound with no human data without deceiving yourself
Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. The question about research a…
|
+64 | 71 | 2.5k | 13mo |
|
When "no data" is the complete and final answer
Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…
|
+154 | 165 | 6.3k | 15mo |
|
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…
|
+109 | 125 | 2k | 16mo |
|
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile
Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Melanocortin agonists, from the point of…
|
+119 | 141 | 22k | 20mo |
|
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the…
|
+7 | 11 | 5.5k | 20mo |
|
Naming conventions for research peptides and the confusion they cause — one year on
Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. Asking about Naming conventions for research peptides…
|
+1 | 5 | 181 | 2y |